Flamel Technologies Announces Projected Release Date of Second Quarter Results, Conference Call.LYON, France -- Flamel Technologies (Nasdaq: FLML) expects to release its second quarter financial results on Wednesday Wednesday: see week. , July July: see month. 27th after the market close. A conference call to discuss Flamel's second quarter results as well as the Company's pipeline and current outlook has been scheduled for Thursday Thursday: see week. , July 28th at 8:30 AM (EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ). A question-and-answer period is expected to follow the discussion of results. To participate in the conference call, investors in the US and Canada are invited to dial 1-800-374-1498. International callers are invited to call 1-706-634-7261. The Conference ID is 8024635. Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel's Medusa(R) technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides. Micropump(R) is a controlled release and taste-masking technology for the oral administration of small molecule drugs. This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements Regulatory requirements are part of the process of drug discovery and drug development. Regulatory requirements describe what is necessary for a new drug to be approved for marketing in any particular country. , uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2004. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion